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The aim of this study was to determine whether Dickkopf-1 (Dkk-1) expression in breast cancer was associated with bone
metastases. We first analysed Dkk-1 expression by human breast cancer cell lines that induce osteolytic or osteoblastic lesions in
animals. Dickkopf-1 levels were then measured in the bone marrow aspirates of hind limbs from eight NMRI mice inoculated with
breast cancer cells that induced bone metastases and 11 age-matched non-inoculated control animals. Finally, Dkk-1 was measured in
the serum of 17 women with breast cancer in complete remission, 19 women with breast cancer and bone metastases, 16 women
with breast cancer and metastases at non-bone sites and 16 healthy women. Only breast cancer cells that induce osteolytic lesions in
animals produced Dkk-1. There was a six-fold increase in Dkk-1 levels in the bone marrow from animals inoculated with MDA-B02
cells when compared with that of control non-inoculated animals (P¼0.003). Median Dkk-1 levels in the serum of patients with
breast cancer and bone metastases were significantly higher than levels of patients in complete remission (P¼0.016), patients with
breast cancer having metastases at non-bone sites (Po0.0001) and healthy women (P¼0.047), although there was a large overlap in
individual levels between the different groups. In conclusion, Dkk-1 is secreted by osteolytic human breast cancer cells lines and
increased circulating levels are associated with the presence of bone metastases in patients with breast cancer. Measurements of
circulating Dkk-1 levels may be useful for the clinical investigation of patients with breast cancer and bone metastases.
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One of the main complications of breast cancer is bone metastases
(Mundy, 2002; Body, 2006a). Although bone metastases from
breast cancer are more often characterised by osteolytic lesions,
osteoblastic or mixed lesions may also occur. Breast cancer cells
secrete different factors (parathyroid hormone-related protein,
interleukins 6, 8, and 11, and prostaglandins) that stimulate the
activity of osteoclasts (bone-lysing cells), leading to the subsequent
degradation of bone (Guise et al, 2005; Yin et al, 2005). Breast
cancer-derived endothelin-1, as a stimulator of the activity of
osteoblasts (bone-forming cells), is probably the main mediator of
osteoblastic lesions (Guise et al, 2005). Endothelin-1 also inhibits
osteoclast activity (Guise et al, 2005), indicating that the formation
of osteoblastic lesions is the result of stimulation of bone
formation and inhibition of bone resorption by breast cancer
cells. It is most likely that the formation of breast cancer osteolytic
lesions reflects stimulation of osteoclasts and inhibition of
osteoblasts. Breast cancer-derived factors involved in the inhibi-
tion of osteoblast activity are however unknown.
It has been recently shown that the Wnt signalling pathway plays
a pivotal role in the differentiation and activity of osteoblastic cells
(Day et al, 2005). There are 19 closely related Wnt genes that have
been identified in humans (Katoh, 2002). The primary receptors of
Wnt molecules are the seven-transmembrane Frizzled proteins
(FRP), each of which interact with a single transmembrane low-
density lipid (LDL) receptor-related protein 5/6 (LRP5/6) (He et al,
2004). Different secreted proteins, including soluble FRP-related
proteins, Wnt inhibitory factor-1 (WIF1), and Dickkopfs (Dkk)
1–4 prevent ligand–receptor interactions and consequently
inhibit the Wnt signalling pathway (Kawano and Kypta, 2003).
Wnt proteins activate several intracellular signalling pathways
through either a ‘canonical’ or a ‘non-canonical’ pathway (Pandur
et al, 2002). In the canonical pathway, secreted Wnt ligands bind to
FRP proteins and regulate the stability of b-catenin (Nusse, 2005).
In the absence of a Wnt signal, b-catenin is constitutively
downregulated by a multicomponent destruction complex (Aberle
et al, 1997; Hart et al, 1998). In the presence of secreted Wnt, this
degradative process is inhibited, leading to the accumulation of
b-catenin in the nucleus and regulation of Wnt-responsive genes
(Eastman and Grosschedl, 1999).
Among the different inhibitors of the canonical Wnt signalling
pathway, genetic disorders indicate that Dkk-1 plays a major role
in the regulation of bone metabolism. For example, in the
syndrome of hereditary high bone density (Boyden et al, 2002),
mutations in the LRP5 gene prevent binding of Dkk-1 to LRP5 and
stimulate growth and differentiation of osteoblasts, leading to
increased bone mass. More recently, it has been shown that Wnt
signalling pathways and Dkk-1 may also play an important role in
malignant bone diseases (Tian et al, 2003; Hall et al, 2005). Tian
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set al (2003) have shown that increased Dkk-1 levels in the plasma
from bone marrow aspirates of patients with multiple myeloma are
associated with the presence of osteolytic lesions. In addition, Dkk-
1 produced by myeloma cells inhibits osteoblast differentiation
in vitro (Tian et al, 2003). Hall et al (2005) have shown that the
inhibition of Dkk-1 expression in osteolytic PC-3 prostate cancer
cells induced in vitro osteoblastic activity in particular phospha-
tase alkaline activity and mineralisation in murine bone marrow
stromal cells. Conversely, the induction of Dkk-1 in the mixed
osteoblastic/osteolytic prostate cancer C4-2B cell line results in
experimental bone metastases with an osteolytic phenotype in
vivo. Dickkopf-1 expression in human breast cancer cell lines has
been recently reported at mRNA level (Schwaninger et al, 2007).
The aim of this study was to determine whether Dkk-1
expression in breast cancer was associated with the presence of
bone metastases.
MATERIALS AND METHODS
ELISA for Dkk-1
Microtitre plates (Nunc ImmunoMaxiSorp, Dutscher, Issy-Les-
Moulineaux, France) were coated with an anti-human Dkk-1
antibody produced in goats immunised with purified, insect cell
line Sf 21-derived, recombinant human Dkk-1 (rhDkk-1) (R&D
System, Minneapolis, MN, USA), diluted in phosphate-buffered
saline (PBS), pH 7.4 (137mM NaCl, 3.3mM KCl, 8mM Na2HPO4,
1.47mM KH2PO4, pH 7.4) and incubated for 2h at room
temperature. Plates were then incubated for 2h at room
temperature with PBS, and 4% BSA (Euromedex, Souffelweyer-
sheim, France). After five cycles of washing with PBS (pH 7.4), 1%
BSA, and 0.1% Tween 20 (washing buffer), rhDkk-1 used as
standard (R&D System), culture supernatant, bone marrow
aspirate or serum were incubated for 2h at room temperature.
After washing, the biotinylated form of the anti-human Dkk-1
antibody was added for 1h at room temperature. Streptavidin–
horseradish peroxidase (Jackson ImmunoResearch Laboratories,
Cambridgeshire, UK) was then added with the substrate solution of
3,30,5,50-tetramethylbenzidine (TMB) (Euromedex). Finally, the
reaction was stopped by the addition of 100ml of 0.2 M H2SO4. The
optical density (OD), which is proportional to the concentration of
Dkk-1 was measured at a wavelength of 450nm corrected for the
absorbance at 650nm. The polyclonal antibodies for Dkk-1 used in
the assay have no significant crossreactivity for human or murine
Dkk-4 and but crossreact at 85% with recombinant murine Dkk-1.
We performed a full technical validation of the ELISA. The
detection limit, defined as the concentration corresponding to 2
s.d. above the mean of 25 determinations of the zero calibrator,
was determined to be 0.25ngml
 1. The intra-assay variation
assessed by 20 measurements of two different serum samples
(mean levels of 13.8 and 42.2ngml
 1) in the same run were 9.0 and
5.9%, respectively. The interassay variation determined by the
measurements of two different serum samples (mean levels of 11.9
and 18.1ngml
 1) in 10 different runs were 14.8–13.6%, respec-
tively. A typical standard curve is shown in Figure 1. The median
dilution recovery of serum was 95% and the dose–dilution (from
20 to 62.5%) curves of two serum samples, one from a healthy
subject and one from a breast cancer patient with bone metastases,
were parallel to the standard curve (Figure 1). Western blot
analysis showed that the antibody used in ELISA test recognises
recombinant human Dkk-1 protein at the expected 35kDa band
(Figure 1 inset).
Western blot analysis for Dkk-1
RhDkk-1 (0.1mgml
 1,1 0ml) was heated 5min at 1001C in loading
buffer (4% SDS, 200mM DTT, 100mM Tris, pH 6.8, 20% glycerol,
0.1% bromophenol blue). Denatured samples were run on a 12%
acrylamide gel. After transfer the PVDF membranes were blocked
overnight in TBS, pH 7.2, 3% milk, and 0.1% Tween 20. The
membranes were then incubated with the anti-human Dkk-1
antibody (R&D System) at a dilution of 1:1000, washed and
incubated with peroxidase-conjugated rabbit anti-goat secondary
antibody (Jackson ImmunoResearch Laboratories/Beckman
Coulter, Roissy, France) at a dilution of 1:10000. The reaction
was revealed using the luminol-based enhanced chemiluminescence
detection system (ECL Amersham Biosciences, Saclay, France).
Cell lines and culture conditions
Human breast cancer cell lines (MDA-MB-231, MCF-7, ZR-75, and
T47D) were obtained from the American Type Culture Collection
(Rockville, MD, USA). The bone features of these cells lines have
been described previously as predominantly osteolytic for MDA-
MB-231, MCF-7 and predominantly osteoblastic for ZR-75 and
T47D (Evans et al, 1991; Hullinger et al, 2000; Guise et al, 2003;
Schwaninger et al, 2007). MDA-MB-231/B02, also named MDA-
B02, is a subclone of the primary tumour cell line MDA-MB-231,
which has been selected for its unique predilection to metastasise
to bone when injected into the tail vein of nude mice as described
previously (Peyruchaud et al, 2001).
Breast cancer cells were grown in DMEM (Life Technologies,
Gibco BRL, Cergy Pontoise, France) supplemented with 10% fetal
calf serum (FCS) (Bio-Media, Boussens, France), 1% (vv
 1)
penicillin/streptomycin and 2mML -glutamine (Life Technologies)
at 371C in a 5% CO2 incubator until confluence. Cells were then
cultured for 24h in the medium described above but without FCS.
The supernatant was collected, centrifuged for 10min at
1000r.p.m., and stored frozen at  701C until analysis for Dkk-1.
Reverse transcription and real-time quantitative PCR
analysis of Dkk-1
Total RNA from breast cancer cell lines was extracted using the
Total RNA Isolation System (Promega, Charbonnie `res, France).
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Figure 1 Typical standard curve of the Dickkopf-1 (Dkk-1) ELISA was
obtained by making serial dilutions of recombinant human Dkk-1 (rhDkk-1)
of known concentrations used as a standard (x axis). The y axis shows the
optical density (OD) obtained for each concentration of the standard (B)
expressed as a percentage of the OD value observed with the highest
concentration of Dkk-1 (B0). Dose–dilution curves of serum samples from
a healthy post-menopausal woman and from a post-menopausal woman
with breast cancer and bone metastases were parallel to the standard
curve. Inset: Western blot indicating that the polyclonal antibody used in
the ELISA recognises human Dkk-1 at the expected 37kDa mass (arrow),
mw¼molecular weight markers.
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scDNA was then obtained using the Moloney murine leukaemia
virus-1 reverse transcriptase (Promega). The following primers
previously described were used for amplification of human Dkk-1
gene: 50-TAGCACCTTGGATGGGTATT-30 (sense) and 50-ATCCT
GAGGCACAGTCTGAT-30 (antisense) generating a PCR product of
110bp (16). GAPDH mRNA expression was analysed in parallel to
control the amount of cDNAs in each reaction. The following
primers were used for amplification of GAPDH gene: 50-
CCTGGCCAAGGTCATCCATGACAAC-30 (sense) and 50-CAGTTC
GAGTAAAGGACCATACTGT-30 (antisense). PCR were run using a
program consisting of 30 cycles of denaturation at 941C for 1min,
annealing at 581C for 1min, and extension at 721C for 1min with a
preincubation of 941C for 2min. Products from RT–PCR were
separated by electrophoresis on a 2% agarose gel and then
visualised with ethidium bromide under ultraviolet light. Human
Dkk-1 mRNA was quantified by real-time PCR using the
QuantiFast SYBR Green PCR kit (Qiagen S.A., Courtaboeuf,
France). Fluorescence was monitored and analysed in a Light
Cycler (Roche Diagnostics, Meylan, France). GAPDH mRNA
expression was analysed in parallel to confirm the use of equal
amount of cDNAs in each reaction and all quantitations were
normalised to this endogenous control. The relative quantitation
value of Dkk-1 mRNA compared to that of GAPDH control gene
was expressed as 2 ðCDkk 1  CGAPDHÞ where CDkk-1 and CGAPDH are the
mean threshold cycle of the PCRs in triplicate for Dkk-1 and
GAPDH, respectively (Yang et al, 2004).
Mice model of breast cancer-induced bone metastases
Female NMRI nude mice of 4 weeks of age (Elevage Janvier, Le
Genest-St-Isle, France) were used. Housing and care, method of
euthanasia, and experimental protocols, were conducted in
accordance with a code of practice established by the Experi-
mentation Review Board from the Laennec School of Medicine,
Lyon, France.
MDA-B02 cells (5 10
5 cells in 100ml of PBS) were inoculated
into the tail vein of anaesthetised mice. Thirty days after tumour
cell inoculation, animals having radiographic evidence of osteo-
lytic lesions were killed. In all B02 inoculated mice both tibias
presented with bone tumour lesions. Consequently, for each
animal, the bone marrow of both tibias was flushed with 200mlo f
DMEM and mixed before analysis for Dkk-1 levels. Similar
experiments were conducted with age-matched control mice that
had not been inoculated with MDA-B02 cells. Bone marrow was
then centrifuged and the supernatant was stored frozen at  701C
until ELISA for Dkk-1.
Radiographs Whole body radiographs (MIN-R2000 films; Kodak,
Rochester, NY, USA) of anaesthesised animals were taken 30 days
after tumour cell inoculation using an MX-20 cabinet X-ray system
(Faxitron X-ray Corporation, Wheeling, IL, USA). The area of
osteolytic lesions of the whole body was measured using a Morpho
computerised image analysis system (Altavista, France), and the
extent of bone destruction per animal was expressed in square
millimetres, as described previously (Peyruchaud et al, 2003).
Bone histology Hind limbs from animals were fixed and
embedded in methylmethacrylate. Seven-micrometre sections of
undecalcified long bones were stained with Goldner’s trichrome.
Histological analyses were performed on longitudinal medial
sections of tibial metaphases using a Morpho computerised image
analysis system (Altavista, France), as described previously
(Peyruchaud et al, 2003).
Circulating Dkk-1 in women with breast cancer
Fasting serum samples from 52 women with breast cancer
consecutively recruited at the Department of Medicine in Institut
Jules Bordet in Brussels were analysed. All serum samples were
kept frozen at  701C until the assay. All patients had a
histologically confirmed breast cancer. Among the 52 women with
breast cancer, 17 had breast cancer in complete remission, 19 had
radiological evidence of bone metastases only, and 16 had
metastases at non-bone sites (hepatic, cutaneous, lymph node,
and lung) (Table 1). Patients were on stable antineoplastic therapy
for at least 4 weeks and did not receive previous treatment with
bisphosphonates within the previous 4 months. Patients did not
have a history of other metabolic bone disease. Serum Dkk-1 levels
was also determined in 16 healthy untreated women (median age
50 years; range: 39–60 years) recruited from a blood donor
program with no history of breast disease or metabolic bone
disease.
Biochemical markers of bone formation and bone
resorption
Serum bone alkaline phosphatase (bone ALP) – a marker of bone
formation – was measured by an immunochemiluminescence
assay using the Ostase reagent on an automatic analyzer (Ostase,
Access, Beckman Coulter, Fullerton, CA, USA). The intra-assay
and interassay CV are less than 3.5 and 8%, respectively. The
crossreactivity of the assay with the liver isoenzyme is of 13%.
Table 1 Characteristics of the patients with breast cancer in complete
remission, breast cancer and bone metastases, and breast cancer and
metastases at non-bone sites
Characteristics
Patients with
breast cancer
in complete
remission
Patients with
breast cancer
and bone
metastases
Patients with
breast cancer
and metastases
at non-bone
sites
No. of patients/
total no. (%) (n¼17) (n¼19) n¼(16)
Age: median year
(range)
58 (46–78) 66 (45–84) 52 (32–72)
Histology
Ductal carcinoma 11/17 (65) 10/19 (52) 10/16 (63)
Lobular carcinoma 3/17 (18) 3/19 (16) 2/16 (12)
Other 0/17 (0) 3/19 (16) 0/16 (0)
Unknown 3/17 (3) 3/19 (16) 4/16 (25)
Type of bone metastases
Lytic 5/19 (26)
Blastic 5/19 (26)
Mixed 5/19 (26)
Unknown 4/19 (22)
Bulk of bone metastases
X5 12/19 (63)
2–5 3/19 (16)
1 3/19 (16)
Unknown 1/19 (5)
Oestrogen receptor
Positive 6/17 (35) 15/19 (78) 9/16 (56)
Negative 5/17 (30) 2/19 (11) 5/16 (31)
Unknown 6/17 (35) 2/19 (11) 2/16 (13)
Therapy
Radiation 0/19 (0) 0/16 (0)
Chemotherapy 3/19 (16) 6/16(38)
Hormonal 13/19 (68) 6/16(38)
Unknown 3/19 (16) 4/16(24)
Dkk-1 and breast cancer bone metastasis
N Voorzanger-Rousselot et al
966
British Journal of Cancer (2007) 97(7), 964–970 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSerum C-terminal crosslinking telopeptide of type I collagen (S-
CTX) was measured by a two-site assay using monoclonal
antibodies raised against an eight amino-acid sequence from the
C-telopeptide of human type I collagen by an automatic analyser
(Elecsys, Roche Diagnostic, Mannheim, Germany). Intra-assay
variation is lower than 3% and interassay variation is lower than
5%.
Statistical analysis
Statistical analyses were performed using the Statistical Analysis
System 8e (SAS Institute Inc., Cary, NC, USA). Differences of bone
marrow Dkk-1 levels between groups of mice were assessed by the
non-parametric Mann–Whitney test. Because serum Dkk-1 levels
were not normally distributed, data were log transformed to
achieve normal distribution before analyses. Differences of
serum Dkk-1 levels between groups of patients were assessed by
ANOVA test. P-values less than 0.05 were considered statistically
significant.
RESULTS
Dickkopf-1 is expressed and secreted by human breast
cancer cell lines that induce osteolytic bone lesions in
animals
The expression of Dkk-1 in human breast cancer cell lines was
analysed by RT–PCR. Agarose gel electrophoresis of RT–PCR
products showed a single correctly sized band corresponding to
Dkk-1 mRNA for each positive sample (Figure 2A). The integrity
and similar relative amounts of mRNAs between conditions were
confirmed using GAPDH as a constitutively expressed marker
(Figure 2A). Real-time RT–PCR Dkk-1 showed significant levels of
expression of Dkk-1 mRNA by MDA-MB-231, MDA B02, and
MCF-7 cell lines. In contrast, the ZR-75 cell line did not express
Dkk-1 and very low mRNA expression was detected in T47D cells
(Figure 2A).
The secretion of Dkk-1 was assessed by ELISA of the culture
supernatant of human breast cancer cell lines. In agreement with
RT–PCR findings, high concentration of Dkk-1 was measured in
the culture supernatants of MDA-MB-231, MDA-B02, and MCF-7
cell lines but not in that of ZR-75 and T47D (Figure 2B).
Dickkopf-1 is present in the bone marrow of bone
metastases bearing limbs from MDA-B02-inoculated mice
All MDA-B02-inoculated mice presented with skeletal radiological
(Figure 3A and C) and histological evidence of bone lesions
(Figure 3B) in both tibias. As shown in Figure 3C, the median
concentration of Dkk-1 in the bone marrow of tibias of mice
inoculated with MDA-B02 was six-fold higher than that of control
mice (P¼0.0003; Figure 3C).
Serum Dkk-1 levels are increased in women with breast
cancer and bone metastases
There was no significant association between serum Dkk-1 and age
when all subjects were considered together or in each group
separately (data not shown).
There was a significant difference in serum Dkk-1 levels between
the different groups of patients with breast cancer and healthy
controls by ANOVA (P¼0.0002). As shown in Figure 4, median
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Figure 2 (A) RT–PCR of Dickkopf-1 (Dkk-1) and GAPDH for the breast cancer cell lines MDA-231, MDA-B02, MCF-7, ZR-75, and T47D. RT–PCR
fragments were separated on a 2% agarose gel and then stained with ethidium bromide. Numbers below the first panel correspond to the relative levels of
Dkk-1 mRNA measured by real-time PCR expressed as the mean±s.d. of the PCRs in triplicate in each cell line. (B) Dkk-1 levels by ELISA in the
supernatant of breast cancer cell lines.
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sserum Dkk-1 levels were significantly higher in women with breast
cancer and bone metastases compared to women with breast cancer
in complete remission (P¼0.016), women with breast cancer
and metastases at non-bone sites (Po0.0001) and healthy
women (P¼0.047). There was no significant difference in serum
Dkk-1 levels between women with breast cancer in remission,
breast cancer at non-bone sites and healthy women. In patients
with bone metastases, there was no significant association of
serum Dkk-1 with the type of lesions, nor the bulk of the bone
metastases (data not shown), although the number of patients in
each subgroup was limited.
Serum bone ALP (13.7±6.2 vs 9.3±2.1ngml
 1, P¼0.03
in women with breast cancer and bone metastases and healthy
controls, respectively) and serum CTX (0.55±0.56 vs
0.22±0.35ngml
 1, P¼0.0004) were significantly higher in women
with breast cancer and bone metastases compared to healthy
women. There was no significant association between serum Dkk-1
and serum bone ALP or CTX in women with breast cancer and
bone metastases (data not shown).
DISCUSSION
In this study, we found that Dkk-1 is produced by human
osteolytic breast cancer cells in vitro and higher serum levels are
associated with the presence of bone metastases in patients with
breast cancer.
Using real-time quantitative RT–PCR and quantitative ELISA,
we demonstrated that Dkk-1 was expressed and secreted in large
amount only by cultured human breast cancer cell lines (MCF-7,
MDA-MB-231, and MDA-B02) known to induce osteolytic bone
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Figure 3 (A) Radiographs from hind limbs of non-inoculated control NMRI mouse and osteolytic bone lesions from female nude mice intravenously
inoculated with MDA-B02 cells. Whole body radiographs were taken 30 days after tumour inoculation with cells. Osteolytic lesions are indicated by arrows.
(B) Representative bone histology of Goldner’s trichrome-stained tibial metaphysis from control and metastatic animals. Bone is stained in green; bone
marrow and tumour cells are stained red. Trabecular bone was completely destroyed and replaced by tumour cells (arrow) in the tibial metaphysis from
metastatic animals. (C) Box plots of bone marrow levels of Dickkopf-1 (Dkk-1) and whole body skeletal extent of radiological lesions in bone of control
(n¼11) and MDA-B02 inoculated (n¼8) NMRI mice. From the bottom up, the box indicates the 25th, 50th (median) and 75th percentiles, while the bars
indicate the 10th and 90th percentiles, respectively. Statistical significance levels between mice groups were obtained from non-parametric Mann–Whitney
test.
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smetastases in mice. Our findings extend those recently reported by
Schwaninger et al (2007), showing that Dkk-1 mRNA was
expressed in the osteolytic MDA-MB-231 breast cancer line in
vitro, whereas osteoblastic breast cancer cell lines T47D and ZR-
75-1 did not express Dkk-1. Moreover, we found high Dkk-1
protein levels in the bone marrow of tumour-bearing legs from
mice inoculated with MDA-B02 breast cancer cells. Our data are in
agreement with the observation that PC-3 prostate cancer cells,
which induce osteolytic lesions in animals, secrete Dkk-1 and that
osteoblastic lesions caused by C4-2B prostate cancer cells revert to
an osteolytic phenotype upon transfection of C4-2B cells with a
plasmid encoding for Dkk-1 (Hall et al, 2005). Because the
antibody we used crossreacts with human and murine Dkk-1, we
could not discriminate between tumour-derived and bone
marrow-derived Dkk-1. Because Dkk-1 could not be detected in
the bone marrow of naive animals, this suggests that MDA-B02
tumour cells were the major source of Dkk-1 in the bone marrow.
However, because both tibias of mice inoculated with MDA-B02
cells presented with bone metastatic lesions, we could not analyse
Dkk-1 levels in non-tumour-bearing legs from inoculated mice,
which would have been the optimal control. Additional mechan-
isms, such as the stimulation by bone-residing breast cancer cells
of Dkk-1 expression by bone marrow cells, may also be involved in
the high local production of Dkk-1. Such a possibility merits
further investigation.
The relevance of our preclinical findings in humans is suggested
by the increased levels of Dkk-1 in the serum of patients with
breast cancer and bone metastases measured by a new sensitive
and reproducible assay that we developed. Although median levels
were significantly higher on a group basis in patients with bone
metastases than in healthy controls and women with breast cancer
and metastases at sites other than bone, there was a large overlap
in individual values between the different groups. If confirmed by
larger studies, this suggests that the measurement of circulating
Dkk-1 would be of limited value to provide an accurate diagnosis
of the presence of bone metastases. We found lower but detectable
levels of Dkk-1 in women with breast cancer in complete remission
and in healthy women. This circulating level probably reflects
basal production of Dkk-1 by various normal cells. Interestingly,
serum Dkk-1 levels in women with breast cancer and metastases at
non-bone sites were lower than values found in patients with bone
metastases and were not different from those of healthy women.
These data suggest that the secretion of Dkk-1 by cancer cells is
increased when present in the bone marrow cavity and/or that
cancer cells increased production of Dkk-1 by the bone marrow
environment through mechanisms, which are yet unknown. As
exemplified with the results obtained in our animal model of
breast cancer bone metastasis, one of these potential mechanisms
could be related to the stimulatory effect of tumour cells on Dkk-1
production by bone marrow cells since, in the absence of tumour
cells, we did not detect Dkk-1 in bone marrow extracts.
Bone-derived RANK-L and several tumour-derived factors
including parathyroid hormone related-protein, interleukins 6, 8,
and 11, and prostaglandins are involved in the development of
breast cancer osteolytic lesions by promoting both osteoclasto-
genesis and osteoclast activity (Guise et al, 2005; Yin et al, 2005).
However, it is also possible that osteolytic breast cancer cells not
only secrete pro-osteoclastic factors, but also inhibitors of
osteoblast functions including Dkk-1 as suggested by our study.
The potential role of tumour-derived Dkk-1 in mediating the
alterations of osteoblastic and/or osteolytic activity associated with
breast cancer however remains to be investigated. Other inhibitors
of the Wnt signalling pathways including Dkk-4, which has been
recently shown to be expressed in primary breast tumours (Wirths
et al, 2003; Katoh and Katoh, 2005) could also play a role in the
pathogenesis of breast cancer bone metastases.
In summary, our data show that Dkk-1 is produced by human
osteolytic breast cancer cells and higher circulating levels were
found in women with breast cancer and bone metastases. Further
studies are required to delineate the role of Dkk-1 in the
physiopathological mechanisms of breast cancer-induced bone
metastases.
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